271980 — Jeil Pharmaceutical Co Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousSmall CapValue Trap

Annual cashflow statement for Jeil Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-14,986	-15,009	5,201	-30,143	32,001
Depreciation
Amortisation
Non-Cash Items	14,760	6,980	5,897	23,613	-1,678
Unusual Items
Purchased R&D
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	10,194	-16,004	-25,846	-1,554	-48,331
Change in Accounts Receivable
Change in Inventories
Change in Other Assets
Change in Accounts Payable
Change in Taxes Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	19,100	-15,147	-4,981	3,213	-5,690
Capital Expenditures	-5,393	-16,958	-9,576	-6,613	-9,077
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	-2,645	4,034	-2,343	-684	-6,260
Sale of Fixed Assets
Sale/Maturity of Investment
Change in Net Investments
Purchase of Investments
Sale of Intangible Assets
Other Investing Cash Flow
Cash from Investing Activities	-8,037	-12,924	-11,919	-7,297	-15,337
Financing Cash Flow Items	27,498	26,001	—	—	-1,560
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	11,069	33,618	18,766	23,063	17,050
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	22,070	5,483	1,545	20,485	-4,601